Finland · Delayed Price · Currency is EUR Nightingale Health Oyj Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 4% in H1, with strong order book and pilots supporting a reiterated 50% full-year growth target. Major partnerships expanded, new contracts secured, and US market entry advanced with the New York lab permit. H2 focus is on targeted sales and commercial scaling.
Fiscal Year 2025
-
Revenue grew 8% year-over-year to €4.7 million, with strong liquidity and no debt. Major milestones included a public sector deal in Finland, U.S. lab expansion, and a new multi-omics research contract. The outlook targets at least 50% revenue growth this year.
-
Revenue grew 35% year-over-year to €2.3 million, with improved profitability and a strong €60 million liquidity position. Expansion continued in key markets, new labs were established, and commercial launches are imminent in Singapore and the U.S.
Fiscal Year 2024
-
Revenue grew 4% year-over-year to EUR 4.36 million, with strong progress in international expansion and major healthcare partnerships. The company remains debt-free, maintains a solid cash position, and is focused on scaling adoption and achieving positive EBITDA.